• Avelumab, sold under the brand name Bavencio, is a fully human monoclonal antibody medication for the treatment of Merkel cell carcinoma, urothelial carcinoma...
    15 KB (1,447 words) - 00:31, 30 September 2024
  • Thumbnail for PD-1 and PD-L1 inhibitors
    non-small cell lung cancer. Avelumab (Bavencio) is a fully human IgG1 antibody developed by Merck Serono and Pfizer. Avelumab is FDA approved for the treatment...
    35 KB (3,450 words) - 03:38, 30 September 2024
  • Thumbnail for Cancer immunotherapy
    was approved for medical use in the United States in September 2024. Avelumab, sold under the brand name Bavencio, is a fully human monoclonal antibody...
    92 KB (12,517 words) - 05:38, 1 October 2024
  • Thumbnail for Pembrolizumab
    Retifanlimab Toripalimab PD-L1 inhibitorsTooltip Programmed death-ligand 1 BMS-202 Atezolizumab Avelumab Durvalumab KN035 Cosibelimab AUNP12 CA-170 BMS-986189...
    79 KB (7,368 words) - 00:29, 30 September 2024
  • studied. Dostarlimab exhibits better efficacy than PD-L1 inhibitors, such as avelumab and durvalumab, in dMMR advanced endometrial cancers. Efficacy of the drug...
    37 KB (3,213 words) - 00:29, 30 September 2024
  • Retifanlimab Toripalimab PD-L1 inhibitorsTooltip Programmed death-ligand 1 BMS-202 Atezolizumab Avelumab Durvalumab KN035 Cosibelimab AUNP12 CA-170 BMS-986189...
    9 KB (603 words) - 00:28, 30 September 2024
  • Thumbnail for Durvalumab
    Retifanlimab Toripalimab PD-L1 inhibitorsTooltip Programmed death-ligand 1 BMS-202 Atezolizumab Avelumab Durvalumab KN035 Cosibelimab AUNP12 CA-170 BMS-986189...
    28 KB (2,721 words) - 04:14, 1 October 2024
  • Thumbnail for Renal cell carcinoma
    results in more progression of the cancer than pembrolizumab, axitinib and avelumab. In comparison to pembrolizumab and axitinib, it probably results in more...
    101 KB (10,959 words) - 10:41, 18 September 2024
  • small cell lung cancer, hepatocellular carcinoma, metastatic melanoma Avelumab Bavencio Merck KGaA and Pfizer PD-L1 2017 Merkel cell carcinoma, urothelial...
    21 KB (2,093 words) - 02:41, 1 September 2024
  • Thumbnail for PD-L1
    trials. Clinically available examples include durvalumab, atezolizumab and avelumab. In normal tissue, feedback between transcription factors like STAT3 and...
    25 KB (3,052 words) - 15:34, 14 September 2024